Personalis (PSNL) vs Veracyte (VCYT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Personalis (PSNL) has outperformed Veracyte (VCYT) over the past year, gaining 85.0% versus a gain of 24.2%. Over five years, VCYT leads with a -3.5% price change compared with -19.5% for PSNL. Veracyte is the larger company by market cap ($3.51 billion vs $1.72 billion), about 2.0 times the size.
Veracyte converts more of its revenue into profit, with a net margin of 12.8% versus -116.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PSNL | VCYT |
|---|---|---|
| Share price | $16.06 | $43.60 |
| Market cap | $1.72B | $3.51B |
| 1-day change | +0.37% | +1.02% |
| YTD return | +101.76% | +3.56% |
| 1-year return | +85.02% | +24.22% |
| 5-year return | -19.46% | -3.45% |
| P/E ratio (TTM) | — | 31.14 |
| Forward P/E | — | 22.36 |
| EPS (TTM) | $-1.09 | $1.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $69.65M | $517.14M |
| Revenue growth (YoY) | -17.69% | +16.01% |
| Net income (latest FY) | $-81.27M | $66.35M |
| Gross margin | 22.65% | 70.10% |
| Operating margin | -126.43% | 11.17% |
| Net margin | -116.69% | 12.83% |
| 52-week high | $18.89 | $60.91 |
| 52-week low | $4.96 | $29.46 |
| Distance from 52-week high | -14.98% | -28.42% |
| Analyst consensus | hold | buy |
| Avg. price target upside | -5.54% | +33.99% |
| Average volume | 3.59M | 1.35M |
| Shares outstanding | 106.80M | 80.39M |
| Employees | 259 | 755 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Veracyte is about 2.0 times larger than Personalis by market value ($3.51B vs $1.72B).
- PSNL has outperformed VCYT by 60.8 percentage points over the past year.
- Veracyte is more profitable, keeping 12.8 cents of every revenue dollar as net income versus -116.7 cents for Personalis.
- Veracyte grew revenue faster in its latest fiscal year (+16.01% vs -17.69%).
About Personalis
PSNL stock →Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.
Health Care · Medical Specialities · 259 employees
About Veracyte
VCYT stock →Veracyte, Inc. operates as a diagnostics company in the United States and internationally.
Health Care · Medical Specialities · 755 employees
PSNL vs VCYT FAQ
Which is bigger, Personalis or Veracyte?
Veracyte (VCYT) is larger, with a market capitalization of $3.51B compared with $1.72B for Personalis (PSNL).
Which stock has performed better over the past year, PSNL or VCYT?
PSNL returned +85.02% over the past 12 months, compared with +24.22% for VCYT (price return, excluding dividends). Past performance does not predict future results.
Are Personalis and Veracyte in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.